Groundbreaking technology for early detection and analysis of cardiovascular disease
| Reference number | |
| Coordinator | Beat Vascular Health AB |
| Funding from Vinnova | SEK 1 973 675 |
| Project duration | November 2023 - October 2025 |
| Status | Completed |
| Venture | Acceleration of deep tech companies |
| Call | Acceleration of deep tech companies 2023 |
Important results from the project
The project has shown that the technology can identify heart disease with high precision and has laid the groundwork for clinical validation of PAD and CAS. The goals for technical development and establishing collaborations were achieved, although patient measurements were delayed. Important outcomes include the development of digital twins, new international collaborations, and an investment plan that strengthens future capital acquisition and commercialization.
Expected long term effects
In the long term, the project will contribute to more accessible and resource-efficient early detection of CVDs, which will help prevent injury or death caused by such conditions. Clinical validation of various cardiovascular diseases will help establish the technology as a new standard for screening, and will enable individualized diagnostics and cardiovascular care. International collaborations and partnerships strengthen commercialization and will accelerate adoption within healthcare.
Approach and implementation
The project was carried out as planned, including research studies, technology development, and preparations for capital acquisition. The completed study produced important results confirming the technology’s potential. The ongoing study is expected to validate its potential for additional cardiovascular diseases. New collaborations were established nationally and internationally. The timeline was affected by external factors, but collaboration worked well and the activities were relevant.